阿普司特治疗中重度掌跖银屑病:双盲随机对照研究
这项双盲、安慰剂对照随机研究纳入100例中重度掌跖银屑病患者,随机接受阿普司特30mg每日两次或安慰剂治疗16周,之后所有患者接受阿普司特至32周。第16周PPPGA 0/1比例在阿普司特组(14%)与安慰剂组(4%)间无显著差异(P=0.1595),但阿普司特在PPPASI 75、PPPASI改善、DLQI及活动损害等次要终点上优于安慰剂。
要点
- 第16周PPPGA 0/1应答率阿普司特14% vs 安慰剂4%,差异无统计学意义。
- 阿普司特在PPPASI 75、PPPASI评分、DLQI及活动损害等次要终点显著优于安慰剂。
- 治疗32周后24%患者达到PPPGA 0/1。
核心结论
- 尽管阿普司特与安慰剂在PPPGA 0/1比例上无显著差异,但多个次要终点显著改善,提示阿普司特可能对中重度掌跖银屑病有治疗作用。
研究设计与样本
- 双盲、安慰剂对照、随机研究,共纳入100例中重度掌跖银屑病患者,随机接受阿普司特30mg每日两次或安慰剂治疗16周,之后所有患者接受阿普司特30mg每日两次至第32周。
主要发现
- 第16周PPPGA 0/1比例:阿普司特组14%,安慰剂组4%,P=0.1595。
- 第16周PPPASI 75比例:阿普司特组22%,安慰剂组8%,P=0.0499。
- 第16周PPPASI变化:阿普司特组-7.4±7.1,安慰剂组-3.6±5.9,P=0.0167。
- 第16周DLQI变化:阿普司特组-4.3±5.1,安慰剂组-0.8±4.5,P=0.0004。
- 第16周活动损害变化:阿普司特组-11.0±22.3,安慰剂组2.5±25.5,P=0.0063。
临床怎么用
- 对于中重度掌跖银屑病患者,阿普司特可考虑作为治疗选择之一,尤其在改善皮损严重度、生活质量及工作活动损害方面可能获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palmoplantar psoriasis is a variant of psoriasis vulgaris which can severely impair quality of life. OBJECTIVES: The main objectives of this double-blind, placebo-controlled, randomized study were to assess the efficacy and impact on quality of life and work productivity of apremilast for the treatment of moderate-to-severe palmoplantar psoriasis. METHODS: A total of 100 patients with moderate-to-severe palmoplantar psoriasis were randomized to either apremilast 30 mg bid or placebo for 16 weeks. At Week 16, all patients received apremilast 30 mg bid until Week 32. The primary endpoint was the proportion of patients who achieved a Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0/1 at Week 16. RESULTS: There was no significant difference in the proportion of patients who achieved a PPPGA of 0/1 at Week 16 between patients randomized to apremilast (14%) and placebo (4%; P = 0.1595). After 32 weeks of treatment with apremilast, 24% of patients achieved a PPGA of 0/1. In addition, apremilast was superior to placebo in achieving Palmoplantar Psoriasis Area Severity Index (PPPASI) 75 (apremilast: 22%; placebo: 8%; P = 0.0499), in improving PPPASI (apremilast: -7.4 ± 7.1; placebo: -3.6 ± 5.9; P = 0.0167), Dermatology Life Quality Index score (apremilast: -4.3 ± 5.1; placebo: -0.8 ± 4.5; P = 0.0004) and in reducing activity impairment (apremilast: -11.0 ± 22.3; placebo: 2.5 ± 25.5; P = 0.0063). CONCLUSION: Despite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a PPPGA of 0/1, the presence of significant differences observed for several secondary endpoints suggests that apremilast may have a role in the treatment of moderate-to-severe palmoplantar psoriasis.
引用
- Bissonnette R, Haydey R, Rosoph LA, et al. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. J Eur Acad Dermatol Venereol. 2017. PMID: 29055155. doi:10.1111/jdv.14647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。